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The pathophysiology of renal sodium retention 
and ascites formation in patients with cirrhosis of the 
liver has become progressively more complicated [1]. 
Conflicting theories of 'underfilling' and 'overflow' 
[21 have been developed to explain the afferent 
mechanisms of impaired volume homeostasis n cir- 
rht)sis. Investigations of efferent mechanisms proved 
to be equally perplexing. Stimulation of the Renin- 
Angiotensin-Aldosterone system may be of impor- 
tance for sodium reabsorption [3], but there is in- 
creasing evidence that this is but one of several fac- 
tors [4,5]. Thus, the impact of other hormonal and 
neural systems on sodium retention was investigated, 
such as the sympathetic nervous ystem [6,7], vaso- 
pressin [8], prostaglandins [9,10] and kailikrein-kinin 
[11]. For about wo decades, the existence of a circu- 
lating natriuretic substance with digoxin-like immu- 
noreactivity, with vasoactive and Na+/K+-ATPase 
inhibiting properties has been postulated [12-15]. A 
deficiency of this natriuretic substance was hypothe- 
sized to be relevant for fluid and electrolyte distur- 
bances in chronic liver disease [16]. However, the in- 
ability to satisfactorily characterize and determine 
this putative natriuretic hormone rendered ifficult 
the elucidation of its role [17]. 
Atrial Natriuretic Factor (ANF) m a novel volume- 
regulating hormone 
As early as 1847, the heart was attributed an im- 
portant role in volume regulation by inducing diure- 
sis following the volume-loading of water immersion 
[18]: ' . . .  if the blood be thus driven (by water im- 
mersion) from the external and internal parts, what 
becomes of the blood? The heart and great vessels, it 
would seem, must be burdened. Such is to a degree 
the case; and it is perhaps the stimulus of this fullness 
and distension or its action on the elasticity of those 
great vessels and the heart that constitutes the reac- 
tion (which leads forth the urine in abundant effu- 
sion).' More than 100 years later, Gauer and Henry 
demonstrated that it was the atria which enhanced 
water and sodium excretion upon a  increase in cen- 
tral blood volume [19,20]. Independently, and un- 
aware of this physiologic research, workers perform- 
ing electron-microscopic studies found multiple 
dense granules in the cytoplasm of atrial muscle cells 
[21,22]. Uniting the physiological importance of the 
atria with this morphological feature of secretory 
atrial myocytes, DeBold in 1981 found a natriuretic 
response to intravenous injection of atrial extracts 
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Fig. 1. Schematic representation of human ANF. Amino acid 
sequence is read from the amino (N)-terminus (left) to the car- 
boxy (C)-terminus (right). 
[23]. It took only 3 more years to identify the Atrial 
Natriuretic Factor (ANF) as a peptide (for a sche- 
matic representation f human ANF, see Fig. 1), and 
to date many of its important properties have been 
characterized. 
For a better understanding of the possible implica- 
tions of this novel volume-regulating hormone in 
liver disease, some significant features of ANF are 
summarized below (see reviews, Refs. 24-34, for 
comprehensive information). 
The biosynthesis of human ANF resembles that of 
most secreted peptides: transcribed messenger RNA 
is translated to a 151-amino-acid pre-prohormone 
ANF-151 with a hydrophobic signal peptide at the N- 
terminus (Fig. 1), which is supposed to expedite 
transport across the endoplasmic reticulum. Subse- 
quent to cleavage of the signal peptide, ANF-126. 
the prohormone is stored in secretory vesicles. ANF- 
126 is further processed enzymatically and secreted 
into the blood, where the biologically active C-termi- 
nal ANF-28 has been defined as the circulating hor- 
mone [27,35,36]. Increased dietary sodium intake 
h s been shown to stimulate ANF release [37]. The 
initial observation that water immersion, increasing 
central venous pressure by shifting extracellular vol- 
ume to the intrathoracic venous bed, rapidly in- 
creases ANF plasma levels in healthy human subjects 
[38] has been confirmed by several investigators 
[39,40,40a]. Elevation of atrial pressure has been 
demonstrated to prompt ANF release [41]. ANF 
plasma levels can be determined by RIA;  however, 
plasma levels measured in different research labora- 
tories in comparable groups of subjects may vary 
considerably (cf. Table 1). This may in part be due to 
different extraction procedures or tracer degrada- 
tion. The ' International Collaborative Study of the 
Proposed International Standard for Atrial Natriu- 
retic Factor on behalf of the American Heart Asso- 
TABLE 1 
ANF PLASMA LEVELS IN PATIENTS WITH CIRRHOSIS (Ci) 
+/-A means (sub)group with/without ascites. Co: values in normal controls, n: numbe  of subjects. Values are means + SE, fmol/ml. 
3 pg correspond to 1 fmol. Data in he table are basically taken from the referenced literature; data of several authors are supple- 
mented by more recent information (personal communication). 
Author [Ref.] Co n Ci n Ci+A n Ci-A n 
Barakat [64] 9 + 2 5 161 + 63 5 
Bonkovsky [65] 64 + 4 11 46 + 3 17 57 + 3 
Burghardt [66] 9 + 1 17 9 + 1 58 8 + 1 18 9 + 1 
Campbell [67] 27 + 6 4 
Epstein [68] 8 + 2 13 10 + 3 8 
Fernandez-Cruz [69] 28 + 2 5 61 + 9 8 
Gerbes[70] 6 + 1 22 9 + 1 41 8 + 1 10 8 + 1 
Gin6s [71] 4 + I 13 14 + 1 35 
J(ippner [72] 33 + 3 21 82 + 10 33 
Morgan [73] 9 + 2 14 120 _+_ 23 7 
Nishiuchi [74] 6 + 1 54 46 + 14 17 
Nozuki [75] 23 + 2 28 17 + 4 5 
Renner [76] 15 + 1 106 31 + 4 20 14 + 3 
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ciation/International Society of Hypertension/World 
Health Organisation' [42] will attempt o clarify the 
existing discrepancies. Furthermore, as antibodies 
recognize, to varying degrees, precursors or circulat- 
ing fragments of ANF-28, characterization f the im- 
munoreactivity determined is advisable, e.g., by 
HPLC techniques [43]. 
ANF binding sites have been found in renal glome- 
rula as well as vasa recta, in cells of the adrenal zona 
glomerulosa, in vascular smooth muscle and en- 
dothelial cells and in various parts of the central ner- 
vous system. Cyclic guanosine monophosphate has 
been claimed to be the intracellular second messen- 
ger of ANF action [44]. Various physiologic actions 
of ANF in the organism are summarized in Fig. 2. 
Enhanced renal sodium and volume excretion are 
supposed to be in part due to an increase of the glo- 
nlerular filtration rate as a result of alterations of re- 
nal hemodynamics induced by pre-glomerular vaso- 
dilation and post-glomerular vasoconstriction [45]. 
In part, actions at other renal sites may increase per- 
fusion of the medullary papillary interstitial space. 
Indeed, ANF relaxes smooth muscles of different 
vascular sites with differing potency. Thus, infusion 
of ANF at doses not affecting systemic blood 
pressure can influence both renal and liver blood 
flow [46]. The observation that antisera to ANF re- 
duce urinary sodium excretion and increase plasma 
renin activity [47] suggests a physiological role for 
this novel hormone in volume regulation. 
Thus, it is by no means urprising that interactions 
with other hormonal systems involved in volume reg- 
ulation have been reported: ANF counteracts the 
Renin-Angiotensin-Aldosterone axis [48] by reduc- 
ing renin as well as aldosterone secretion and by re- 
laxing angiotensin-constricted v ssels [49-51]. It was 
speculated that ANF, elevated in primary aldostero- 
nism [52], in turn might be stimulated by angiotensin 
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Fig. 2. Effects of ANF in the body. CNS = central nervous system, ECV = extracellular volume, GFR = glomerular filtration rate, 
MAP = mean arterial pressure, PCWP = pulmonary capillary wedge pressure, RAP = right atrial pressure. 
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II, thus explaining the natriuresis observed after an- 
giotensin infusion [53]. ANF is stimulated by miner- 
alocorticoid administration [54,55], thus being a po- 
tential mediator of the 'escape phenomenon'; though 
it certainly is not identical with the Na÷/K+-ATPase - 
inhibiting natriuretic hormone, ANF seems to be an 
excellent candidate for the long-elusive 'third factor' 
[56]. A number of observations suggest interactions 
of ANF with the sympathicoadrenergic system: Infu- 
sion of norepinephrine provokes ANF release from 
isolated rat hearts [57], this stimulation being in- 
hibited by alpha-adrenoceptor blockade with phen- 
tolamine [57]; ANF may prevent norepinephrine-in- 
duced acute r nal failure [58] and may reduce nor- 
epinephrine-induced blood pressure levations [59]; 
and a relationship to vasopressin is suggested by the 
observation of an increased ANF secretion following 
vasopressin i fusion [60,61], whereas ANF adminis- 
tration inhibits stimulated vasopressin crease [62]. 
This brief outline of the characteristics of ANF 
helps explain why the discovery of this novel volume- 
regulating hormone, linking the heart - now known 
to be an endocrine organ - with kidney, adrenal cor- 
tex, microvasculature and the brain, has created so 
much excitement. Cardiologists, nephrologists and 
hepatologists are awaiting information on the possi- 
ble impact of ANF in various diseases. This review 
will concentrate on the role of ANF in cirrhosis; in 
this pathologic state, the splanchnic and peripheral 
subcompartment are volume-overloaded, in contrast 
to the central volume-stimulation f congestive heart 
failure. 
Plasma levels 
As mentioned above, in cirrhotic patients with 
splanchnic sequestration of extracellular volume, 
supporters of the 'underfilling' theory might expect a 
diminution of centrally effective blood volume, re- 
sulting in decreased stimulation of ANF release and 
thus in lower ANF plasma levels. In contrast, if one 
believes in the 'overflow' theory of increased effec- 
tive blood volume, elevated ANF levels might be an- 
ticipated. The first report concentrating on ANF 
plasma levels in cirrhosis [63] demonstrated in 9 cir- 
rhotics without and 10 with ascites that there was no 
absolute deficiency of plasma ANF as compared to 
controls. Concentrations in patients with ascites did 
not differ from those in the other cirrhotics. In the 
course of the year that has elapsed since the appear- 
ance of that report and the submission of this review. 
several groups have investigated ANF levels in cir- 
rhosis (Refs. 64-77; cf. Table 1). Levels lower than 
in controls were reported by one group only [65], in 
cirrhotics with ascites, In all of the studies that evalu- 
ated the presence or absence of ascites, the ANF con- 
centrations observed were not markedly different 
from normal in the cirrhotics without ascites [65,66. 
70,76]. In patients with ascites, ANF values equal to 
[66,68,70,75,77], lower [65] or higher [67,69,72-74, 
76] than normal have been found. Differences in a 
number of factors might cause such different results: 
plasma extraction, radioimmunoassay, posture of the 
subjects, restriction of dietary sodium and water, di- 
uretic treatment, or possibly variations in hepatic and 
renal clearance of ANF [78]. The atrial content of 
ANF, estimated by bioassay, was found to be higher 
than normal in human cirrhotic subjects [79], but 
lower than normal in cirrhotic rats [80]. 
Patients with congestive heart failure, character- 
ized by central volume overload, exhibit markedly 
elevated ANF levels ranging from several up to one 
hundred times higher than ormal [43,81,82]. Inter- 
estingly, further characterization f the immunoreac- 
tive ANF by HPLC techniques revealed an immuno- 
reactive component of higher molecular weight in 
some of these patients (Fig. 3). It was speculated that 
the rate of compensatory ANF secretion upon the 
volume stimulus exceeded the capacity of the 
processing enzymes, thus resulting in the release of 
immature ANF of possibly reduced biological activi- 
ty [83]. However, the above-mentioned reports on 
markedly elevated ANF plasma levels in cirrhotic pa- 
tients do not provide a further characterization f the 
immunoreactivity. High performance gel permeation 
chromatography of ANF in cirrhosis has been per- 
formed in a few patients (Ref. 83, Fig. 3) and re- 
vealed only trace amounts of higher molecular 
weight forms. 
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Fig. 3. Molecular weight pattern of immunoreactive ANF in a 
representative h althy subject (a), a patient with severe con- 
gestive heart failure (b) and a patient with cirrhosis (c). In 
healthy subjects, plasma ANF consists virtually exclusively of 
ANF-28. In patients with CHF, higher molecular weight forms 
can be found that are to be seen only in trace amounts in tl~e cir- 
rhotic patient. Molecular weight calibration of the TSK 125 
Bio-Sil column is indicated at the top of the illustration. 
ANF release 
Apart from inappropriate plasma levels or altera- 
tions of posttranslational processing, release of ANF 
to volume stimulation might be impaired. Head-out 
water immersion has been shown to be a useful mod- 
el for investigating the response of the ANF system 
to acute volume stimulation in healthy subjects [38]. 
One-hour immersion in a thermoneutral bath induces 
a two-fold rise in ANF plasma levels (Fig. 4). Numer- 
ous investigations had shown that water immersion 
can also be conveniently used in cirrhotic patients 
[84] to study volume regulation. ANF release after 
1-h immersion has been found to be normal in cir- 
rhotics without ascites, but reduced to about one-half 
in the presence of ascites [85] (Fig. 5). These findings 
are at variance with another study demonstrating 
ANF increases twice as high as in normals in patients 
with ascites and edema [68]. Another group reported 
blunted ANF stimulation following water immersion 
in cirrhotics with ascites [69]. In view of a lack of in- 
crease in their control group, however, this assertion 
has been questioned [86]. 
Renal response 
The natriuretic response to levated ANF follow- 
ing water immersion has been found to be variable 
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Fig. 4. ANF plasma levels before, during 60 rain water immer- 
sion, and subsequent to immersion. Mean values and standard 
deviations of 12 healthy subjects. 
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F ig .  5. Percent increase of plasma ANF during water immer- 
sion. Mean values of 7 patients with and 7 patients without as- 
cites. Whereas cirrhotics without ascites exhibit normal in- 
crease, stimulation isblunted in patients with ascites. 
[68,70]. Thus, stimulus-response coupling may be im- 
paired in cirrhosis [87]. However, in patients with re- 
fractory ascites, insertion of a peritoneo-venous 
shunt increased ANF plasma levels, with a corre- 
sponding rise in natriuresis and diuresis [66,67]. Infu- 
sion of synthetic human ANF-28 in healthy subjects 
results in marked diuresis and natriuresis [88-90]. 
Similar beneficial effects have been observed in pa- 
tients with cardiovascular disease, despite increased 
basal values [82,91]. The initial experience in a pa- 
tient with refractory ascites, with infusion of 50 
ng/kg/min for 60 min and resultant diuresis (Fig. 6) 
[92], encouraged other studies with therapeutic as- 
pects. Eight of 14 cirrhotics responded to an i.v. bo- 
lus injection of 1 #g/kg with a significant increase of 
sodium excretion and urine flow, similar to the re- 
sponse of healthy controls [93]. Six patients, howev- 
er, showed no marked effects. Plasma aldosterone 
was decreased in all cirrhotics, an effect that has not, 
as yet, been observed in all healthy subjects tudied 
[89,90]. Renal response to ANF seems to be highly 
variable [94,95], and limited effects of continuous in- 
fusion have been reported [94]. At this early stage of 
investigation of ANF in liver disease, it seems impos- 
sible to make unequivocal conclusions as to any 
dysfunction of stimulus-response-coupling. 
Therapeutic aspects 
Conventional diuretic therapy of ascites has been 
shown to involve hazards [96]. Thus, application of a 
naturally occurring diuretic hormone might seem 
promising. The diuretic, natriuretic and anti-hyper- 
tensive effects of ANF could be of therapeutic rele- 
vance in clinical practice, especially when long-acting 
analogues will be developed. In patients with end- 
stage heart failure on intensive care, i.v. ANF admin- 
istration might prove helpful in improving cardiopul- 
monary hemodynamics (Arendt, R.M. and Gerbes. 
A.L., unpublished observation). Upon administer- 
ing the peptide to cirrhotics, in whom the Renin-An- 
giotensin-Aldosterone system is often activated to 
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Fig. 6. Effects of ANF infusion in a patient with cirrhosis and 
ascites (from Ref. 92). 
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maintain their blood pressure, special attention 
should be given to the antihypertensive effects. Slight 
to marked decreases of mean arterial pressure fol- 
lowing ANF injection have been observed [93]: 2-10 
minutes after injection, mean arterial pressure de- 
creased more markedly in cirrhotics (18 + 5 mm Hg) 
than in controls (8 + 4 mm Hg) [93]. However, with 
its modes of action differing from that of established 
diuretics [97], the therapeutic potentials of ANF 
should be studied in greater detail. 
Summary 
The discovery of the first well-defined natriuretic 
hormone, the Atrial Natriuretic Factor (ANF), has 
prompted research on its impact on volume regula- 
tion in health and disease. The natriuretic, diuretic, 
and smooth muscle-relaxing properties uggest an 
important role of this novel hormone in pathophysio- 
logical states with sodium or volume retention, such 
as congestive h art failure or cirrhosis of the liver. In- 
vestigations on the implications of ANF in liver dis- 
ease have been performed for little more than I year, 
and results are still controversial in many respects. 
At present, it seems very likely that there is no abso- 
lute deficiency of plasma ANF in patients with cir- 
rhosis. Moreover, elevated plasma levels in cirrhot- 
ics with ascites have been reported by several groups. 
However, as yet, a molecular characterization f this 
increased immunoreactivity s still lacking. There is 
disagreement on the reduced release of and renal re- 
sponse to ANF in subgroups of cirrhotics; however, 
stimulus-response-coupling might be impaired. Fur- 
ther studies are needed to elucidate the pathophysio- 
logical implications and therapeutical potential of 
ANF in patients with chronic liver disease. 
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